Kairos Pharma, Ltd.

NYSEAM:KAPA Stock Report

Market Cap: US$6.4m

Kairos Pharma Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of KAPA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies1,173,5725.48%
Institutions1,486,0346.94%
Individual Insiders6,820,00031.9%
General Public11,931,59255.7%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.1%.

Top Shareholders

Top 20 shareholders own 44.27% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
25%
John Yu
5,351,171US$1.6m0%no data
5.48%
Technomedics Management & Systems, Inc
1,173,572US$352.0k0%no data
5.3%
Neil Bhowmick
1,135,317US$340.5k0%no data
4.13%
Armistice Capital LLC
884,938US$265.4k0%0.01%
1.08%
Vanguard Capital Management, LLC
231,878US$69.5k0%no data
0.66%
Ramachandran Murali
142,191US$42.6k0%no data
0.66%
Douglas Samuelson
140,367US$42.1k0%no data
0.52%
Geode Capital Management, LLC
111,290US$33.4k52.8%no data
0.3%
Vanguard Fiduciary Trust Company
63,884US$19.2k0%no data
0.22%
Hyun Bae
47,620US$14.3k0%no data
0.21%
SevenBridge Financial Group, LLC
44,286US$13.3k0%no data
0.21%
Aptus Capital Advisors, LLC
44,286US$13.3k0%no data
0.18%
Two Sigma Investments, LP
39,543US$11.9k-57.9%no data
0.11%
State Street Global Advisors, Inc.
24,100US$7.2k0%no data
0.1%
Hudson River Trading LLC
21,575US$6.5k1.2%no data
0.076%
Two Sigma Securities, LLC
16,247US$4.9k0%no data
0.018%
Tower Research Capital Europe Limited
3,962US$1.2k-6.27%no data
0.016%
Hansoo Michael Keyoung
3,334US$999.80%no data
0.00016%
Blackstone Inc.
35US$10.30%no data
0.00005%
Citigroup Inc.
10US$3.20%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/31 22:10
End of Day Share Price 2026/07/31 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kairos Pharma, Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.
Joseph PantginisH.C. Wainwright & Co.
Jason McCarthyMaxim Group